Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT01841736 | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | active not recruiting | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 |
| clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02270814 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma(CACTUX) | active not recruiting | Phase 2 | 74 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | active not recruiting | Phase 3 | 819 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT03371719 | Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial | active not recruiting | Phase 2 | 298 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | active not recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04427293 | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05668858 | A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 70 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07791602 | Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer(IDEAL-RT) | active not recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01064466 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03811002 | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | active not recruiting | Phase 3 | 544 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06668961 | A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00334815 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03204123 | PSMA PET Imaging of Recurrent Prostate Cancer | active not recruiting | Phase 2 | 1,171 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04034927 | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05063565 | TheraSphere With Durvalumab and Tremelimumab for HCC(ROWAN) | active not recruiting | Phase 2 | 100 | Boston Scientific CorporationINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06598137 | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy | active not recruiting | — | 645 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04510740 | Liver Cancer Registry Platform(JADE) | active not recruiting | — | 1,000 | iOMEDICO AGINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03801876 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | active not recruiting | Phase 3 | 300 | NRG OncologyOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT01893307 | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer | active not recruiting | Phase 3 | 440 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT03655002 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04535401 | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | active not recruiting | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05245682 | Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | active not recruiting | Early Phase 1 | 10 | Emory UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | active not recruiting | Phase 2 | 46 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT05064150 | Neuroendocrine Tumors - Patient Reported Outcomes(NET-PRO) | active not recruiting | — | 2,539 | University of IowaOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06027268 | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT) | active not recruiting | Phase 2 | 36 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06223568 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06651957 | Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)(ULACNet-104) | active not recruiting | — | 217 | University of California, San FranciscoOTHER | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06995053 | Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial(ILLUSION) | active not recruiting | N/A | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials